Lexicon Pharmaceuticals, Inc.

Lexicon reported Q2 2026 total revenues of $0.7 million versus $28.9 million in Q2 2025, with the prior-year period including $27.5 million of licensing revenue from Novo Nordisk and net sales of INPEFA. Research and development expense was $17.4 million versus $15.7 million a year ago, SG&A was $9.8 million versus $9.4 million, and net loss was $31.8 million, or $0.07 per share, compared with net income of $3.3 million, or $0.01 per share, in Q2 2025. Cash, cash equivalents and short-term investments were $190.6 million at June 30, 2026, up from $125.2 million at December 31, 2025. For 2026, the company reiterated operating expense guidance of $100 million to $110 million, including R&D of $63 million to $68 million and SG&A of $37 million to $42 million. Management said SONATA-HCM top-line data are expected in Q1 2027, and Zynquista NDA resubmission is now anticipated in Q4 2026.

Mike Exton framed the quarter around two late-stage catalysts: SONATA-HCM enrollment completion and progress toward a Zynquista filing. He called SONATA a major milestone and said the next 12 months could be one of the most transformational periods in Lexicon’s history, emphasizing that sotagliflozin could be a first-and-only option across the HCM spectrum. His tone was upbeat and confidence-building, but still tied to execution and upcoming data/readouts.

Scott Coiante focused on the quarter’s reported numbers and the balance sheet. He noted the decline in revenue was driven by the lack of prior-year licensing revenue, while R&D rose due to higher external costs for SONATA-HCM and SG&A remained relatively stable. He also highlighted a $4.3 million loss on early extinguishment of debt from repaying Oxford Finance, the new $100 million Hercules facility with an initial $55 million tranche funded, and reiterated 2026 expense guidance of $100 million to $110 million with R&D at $63 million to $68 million and SG&A at $37 million to $42 million.

Analysts focused on SONATA’s patient mix and what it means for regulatory and commercial value, plus whether a positive overall readout might support future use in both obstructive and nonobstructive HCM. Management said the trial was designed as a pragmatic overall-population study, that the primary endpoint will remain the week-26 KCCQ in the overall population, and that the over-enrollment increases confidence in power. Questions on Zynquista centered on the delayed resubmission timeline; management said the delay reflects the time needed to assemble and format STENO1 data for FDA, not a lack of adequate exposure or favorable DKA findings, and they reiterated that an end-of-October submission is possible.